HealthTronics bids for EndoCare
This article was originally published in The Gray Sheet
Executive Summary
In a letter to Endocare's board of directors, released after the markets closed on Aug. 6, HealthTronics says it wants to buy the cryosurgery device company for $2.28 per share, about a 20% premium over Endocare's Aug. 6 closing stock price. Endocare responds that its board will review the unsolicited bid and consult with advisers. Both companies have a focus on prostate cancer. In second-quarter earnings released Aug. 6, Endocare's sales were flat at $7.9 million
You may also be interested in...
Endocare rejects acquisition bid
Cryocare prostate cancer cryoablation device developer Endocare rejects HealthTronics' unsolicited acquisition proposal, the company announces Aug. 13. HealthTronics, a urology service provider and device distributor, offered to pay $2.28 per share Aug. 6, but Endocare's board unanimously agreed the offer is inadequate (1"The Gray Sheet" Aug. 11, 2008, In Brief)
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.